An emerging generation of endocrine therapies in breast cancer: a clinical perspective

$ 29.50

4.8
(215)
In stock
Description

New Therapy Targets Breast Cancer Metastases in Brain

Cancers, Free Full-Text

Randomized Phase II Trial of Fulvestrant Plus Everolimus or

The immunomodulatory effects of endocrine therapy in breast cancer, Journal of Experimental & Clinical Cancer Research

Current and Upcoming Treatment Strategies After CDK4/6 Inhibitors

Randomized Phase II Trial of Fulvestrant Plus Everolimus or

ZB716, a steroidal selective estrogen receptor degrader (SERD), is

ZB716, a steroidal selective estrogen receptor degrader (SERD), is

Pharmaceutics, Free Full-Text

IJMS, Free Full-Text

Cancers, Free Full-Text

New Insights into Extracellular Vesicles between Adipocytes and

Randomized Phase II Trial of Fulvestrant Plus Everolimus or

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative

Endocrine treatment in breast cancer: Cure, resistance and beyond